| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Research Support, Non-U.S. Gov't
- Language: English
- [Pharmacogenet Genomics] 2024 Jun 01; Vol. 34 (4), pp. 105-116. <i>Date of Electronic Publication: </i>2024 Mar 07.
- MeSH Terms: Cytochrome P-450 CYP2C9* / genetics ; Vitamin K Epoxide Reductases* / genetics ; Warfarin* / adverse effects ; Warfarin* / administration & dosage ; Polymorphism, Single Nucleotide* ; Anticoagulants* / adverse effects ; Anticoagulants* / administration & dosage ; Asian People* / genetics ; Humans ; Female ; Male ; Middle Aged ; Aged ; Hemorrhage / chemically induced ; Hemorrhage / genetics ; China ; Adult ; Genotype ; Genetic Association Studies ; East Asian People
- References: Zhou L, Ding Y, Gao Y, Yang B, Bao J, Ma J. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements. Expert Opin Drug Metab Toxicol 2020; 16:1–9. ; Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40:587–603. ; McDowell TY, Lawrence J, Florian J, Southworth MR, Grant S, Stockbridge N. Relationship between international normalized ratio and outcomes in modern trials with warfarin controls. Pharmacotherapy 2018; 38:899–906. ; Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage over anticoagulation and other adverse outcomes in Indian population. Eur J Pharmacol 2013; 710:80–84. ; Shukla A, Jain A, Kahalekar V, Bendkhale S, Gogtay N, Thatte U, et al. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd–Chiari syndrome on warfarin. Hepatol Int 2019; 13:214–221. ; Juurlink DN. Drug interactions with warfarin: what clinicians need to know? CMAJ 2007; 177:369–371. ; Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329–2333. ; Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, Frascaro M, et al. A new warfarin dosing algorithm including VKORC1 3730 G> A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol 2012; 68:1167–1174. ; Tie JK, Stafford DW. Structural and functional insights into enzymes of the vitamin K cycle. J Thromb Haemost 2016; 14:236–247. ; D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105:645–649. ; Tan SL, Li Z, Zhang W, Song GB, Liu LM, Peng J, et al. Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. Eur J Clin Pharmacol 2013; 69:1769–1775. ; Li ZJ, Liu X. Effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirement in Central China Han populations. Trop J Phar Res 2018; 17:2269–2274. ; Molden E, Okkenhaug C, Solberg EE. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1* 2B carriers in warfarin-treated patients with excessive INR response. Eur J Clin Pharmacol 2010; 66:525–530. ; Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999–1008. ; Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol & Ther 2005; 78:540–550. ; Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96:1816–1819. ; Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019–1026. ; Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690–1698. ; Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717–719. ; Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784–792. ; Suzuki S, Yamashita T, Kato T, Fujino T, Sagara K, Sawada H, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007; 71:761–765. ; Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13:247–252. ; Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84:83–89. ; Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83:312–321. ; Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118:511–520. ; Zuo Q, Li L, Zhong M, Chen G, Xio J. Correlation between CYP2C9 gene polymorphism and warfarin dose in Chinese Han population with coronary heart disease. Cell Mol Biol (Noisy-le-grand) 2021; 67:157–163. ; Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 2012; 107:1083–1091. ; Wattanachai N, Kaewmoongkun S, Pussadhamma B, Makarawate P, Wongvipaporn C, Kiatchoosakun S, et al. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. Eur J Clin Pharmacol 2017; 73:973–980. ; Subsuphan B, Chinpaisal C, Pongchaidecha M, Phanthabordeekorn W, Watana S. Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients. Arch Pharm Pract 2016; 7:18–25. ; Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 2009; 65:1097–1103. ; Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006; 80:169–178. ; Ngow H, Teh L, Langmia I, Lee W, Harun R, Ismail R, et al. Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study. Xenobiotica 2008; 38:641–651. ; Miao L, Yang J, Huang C, Shen Z. Contribution of age body weight and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63:1135–1141. ; Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, et al. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol 2012; 96:719–728. ; Lu Y, Yang J, Zhang H, Yang J. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors. Clin Pharmacokinet 2013; 52:567–581. ; Lin M, Zhang J, Qiu H, Xie X, Song H. Pharmacogenetics-based warfarin dose prediction algorithm for patients with heart valve replacement in Southeast China. Genet Mol Res 2017; 16:1–13. ; Liang R, Li L, Li C, Gao Y, Liu W, Hu D, et al. Impact of CYP2C9* 3 VKORC1 -1639 CYP4F2 rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 2012; 34:120–125. ; Jiang NX, Ge JW, Xian YQ, Huang SY, Li YS. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients. Biomed Rep 2016; 4:453–458. ; Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19:226–234. ; Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2010; 70:234–240. ; Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes JR, et al. Estimation of warfarin maintenance dose based on VKORC1 (− 1639 G> A) and CYP2C9 genotypes. Clin Chem 2007; 53:1199–1205. ; Yuan HY, Chen JJ, Lee MM, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14:1745–1751. ; Li Y, Zhu J, Ding J. VKORC1 -1639G/A and 1173 C/T genetic polymorphisms influence individual differences in warfarin maintenance dose. Genet Test Mol Biomarkers 2015; 19:488–493. ; Wijaya A, Bo JT, Jun H, Ping JW, Bin J, Jie CH, et al. The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population. Med J Indones 2012; 21:108–112. ; Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112:1013–1021. ; Teh L, Langmia I, Fazleen Haslinda M, Ngow H, Roziah M, Harun R, et al. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9* 3 among patients on warfarin. J Clin Pharm Ther 2012; 37:232–236. ; Mazzaccara C, Conti V, Liguori R, Simeon V, Toriello M, Severini A, et al. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PLoS One 2013; 8:e71505. ; Li S, Zou Y, Wang X, Huang X, Sun Y, Wang Y, et al. Warfarin dosage response related pharmacogenetics in Chinese population. PLoS One 2015; 10:e0116463. ; Koshy L, Vb R, Ben MP, Kishor P, Sudhakaran P, Abdullakutty J, et al. Pharmacogenetic variants influence vitamin K anticoagulant dosing in patients with mechanical prosthetic heart valves. Pharmacogenomics 2022; 23:475–485. ; Khalighi K, Cheng G, Mirabbasi S, Khalighi B, Wu Y, Fan W. Linkage disequilibrium between the CYP2C19* 2* 17 and CYP2C9* 1 alleles and impact of VKORC1 CYP2C9 CYP2C19 gene polymorphisms and gene–gene interactions on warfarin therapy. J Thromb Thrombolysis 2017; 43:124–129. ; Khaleqsefat E, Khalaj-Kondori M, Bonyadi MJ, Soraya H, Askari B. The Contribution of VKORC1 and CYP2C9 genetic polymorphisms and patients’ demographic characteristics with warfarin maintenance doses: a suggested warfarin dosing algorithm. Iran J Pharm Res 2020; 19:77. ; Gu Q, Kong Y, Schneede J, Xiao YB, Chen L, Zhong QJ, et al. VKORC1 -1639G> A CYP2C9 EPHX1 691A> G genotype body weight and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur J Clin Pharmacol 2010; 66:1217–1227. ; Gan GG, Phipps ME, Lee MM, Lu LS, Subramaniam RY, Bee PC, et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 2011; 90:635–641. ; Farajzadeh-Dehkordi M, Samiee-Rad F, Farzam SS, Javadi A, Cheraghi S, Hamedi-Asl D, et al. Evaluation of a warfarin dosing algorithm including CYP2C9 VKORC1 and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population. Pharmacol Rep 2023; 75:695–704. ; Alrashid MH, Al-Serri A, Alshemmari SH, Koshi P, Al-Bustan SA. Association of genetic polymorphisms in the VKORC1 and CYP2C9 genes with warfarin dosage in a group of Kuwaiti individuals. Mol Diagn Ther 2016; 20:183–190. ; Sridharan K, Modi T, Bendkhale S, Kulkarni D, Gogtay JN, Urmila MT. Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: a case-control study. Curr Clin Pharmacol 2016; 11:62–68. ; Topić E, Štefanović M, Zibar L, Samardžija G, Balen S, Včev A, et al. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy. Coll Antropol 2008; 32:557–564. ; Pourgholi L, Goodarzynejad H, Mandegary A, Ziaee S, Talasaz AH, Jalali A, et al. Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicol Appl Pharmacol 2016; 309:37–43. ; Lima M, Ribeiro G, Mesquita E, Victer P, Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 2008; 64:9–15. ; Giansante C, Fiotti N, Altamura N, Pitacco P, Consoloni L, Scardi S, et al. Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up. J Thromb Thrombolysis 2012; 34:506–512. ; Bedewy AM, Showeta S, Mostafa MH, Kandil LS. The influence of CYP2C9 and VKORC1 gene polymorphisms on the response to warfarin in Egyptians. Indian J Hematol Blood Transfus 2018; 34:328–336. ; Sano E, Li W, Yuki H, Liu X, Furihata T, Kobayashi K, et al. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis. J Comput Chem 2010; 31:2746–2758. ; Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol 2012; 73:340–347. ; An S, Lee K, Chang B, Gwak H. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. J Clin Pharm and Ther 2014; 39:314–318. ; Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 2013; 168:4234–4243. ; Bazan N, Sabry N, Rizk A, Mokhtar S, Badary OA. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Ir J Med Sci 2014; 183:161–172. ; LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, et al. Integrating genomic based information into clinical Warfarin (Coumadin®) management: an illustrative case report. Conn Med 2008; 72:399–403. ; Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC. Polymorphisms in VKORC 1 have more impact than CYP2C9 polymorphisms on early warfarin I nternational N ormalized R atio control and bleeding rates. Br J Haematol 2012; 158:256–261. ; Limdi N, Wiener H, Goldstein J, Acton R, Beasley T. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis 2009; 43:119–128. ; Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100:229–239.
- Substance Nomenclature: EC 1.14.13.- (Cytochrome P-450 CYP2C9) ; EC 1.17.4.4 (Vitamin K Epoxide Reductases) ; 5Q7ZVV76EI (Warfarin) ; EC 1.17.4.4 (VKORC1 protein, human) ; EC 1.14.13.- (CYP2C9 protein, human) ; 0 (Anticoagulants)
- Entry Date(s): Date Created: 20240312 Date Completed: 20240429 Latest Revision: 20240429
- Update Code: 20240429
|
